Cuvposa

Active Ingredient(s): Glycopyrrolate
FDA Approved: * July 28, 2010
Pharm Company: * SHIONOGI PHARMA
Category: Ulcer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Cuvposa Overview

Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has few to no central effects. It is available in oral, intravenous, topical, and inhaled forms. It is a synthetic quaternary ammonium compound. The cation, which is the active moiety, is called glycopyrronium (INN)[1] or glycopyrrolate (USAN). In June 2018, glycopyrronium was approved by the FDA to treat excessive underarm sweating,...

Read more Cuvposa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glycopyrrolate

Recent Cuvposa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glycopyrrolate
  • Injection: 0.2mg/ml
  • Powder: 15.6mcg, 15.6mcg/inh
  • Solution: 0.2mg/ml, 0.2mg/ml (0.2mg/ml), 0.4mg/2ml (0.2mg/ml), 0.6mg/3ml (0.2mg/ml), 1mg/5ml, 1mg/5ml (0.2mg/ml), 25mcg/ml
  • Tablet: 1.5mg, 1mg, 2mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cuvposa: (2 results)

Sorted by National Drug Code
  • 0259-0501 Cuvposa 1 mg/5ml Oral Liquid by Merz Pharmaceuticals, LLC
  • 59630-206 Cuvposa 1 mg/5ml Oral Solution by Shionogi Pharma, Inc.

Other drugs which contain Glycopyrrolate or a similar ingredient: (12 results)